Laleh Khodadadi

Berlin, BE 10117, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Increased Type I Interferon Activity with Concurrent Plasmablast Expansion Identifies Systemic Lupus Erythematosus Patients with Poor Outcomes.

Increased Type I Interferon Activity with Concurrent Plasmablast Expansion Identifies Systemic Lupus Erythematosus Patients with Poor Outcomes.

Journal: International journal of molecular sciences

Published: February 28, 2026

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.

Journal: European journal of immunology

Published: September 08, 2025

Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.

Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.

Journal: Nature communications

Published: July 11, 2025

Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases.

Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: July 13, 2020

Pathogenic memory plasma cells in autoimmunity.

Pathogenic memory plasma cells in autoimmunity.

Journal: Current opinion in immunology

Published: May 31, 2019

Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies.

Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies.

Journal: European journal of immunology

Published: February 12, 2019

The Maintenance of Memory Plasma Cells.

The Maintenance of Memory Plasma Cells.

Journal: Frontiers in immunology

Published: December 10, 2018

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.

Journal: European journal of immunology

Published: January 12, 2018

CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice.

CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice.

Journal: European journal of immunology

Published: March 01, 2017

Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy.

Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy.

Journal: Arthritis research & therapy

Published: May 24, 2015

Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice.

Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice.

Journal: PloS one

Published: March 11, 2015

Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.

Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.

Journal: Arthritis research & therapy

Published: July 23, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026